The firm has strong confidence aTyr’s lead program efzofitimod will be successful in its ongoing Phase 3 study in pulmonary sarcoidosis, with topline results expected in Q3 2025. The Phase 3 EFZO-FIT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback